Impaired dopamine metabolism in Parkinson’s disease pathogenesis

[1]  W. Burke,et al.  Aldehyde adducts inhibit 3,4‐dihydroxyphenylacetaldehyde‐induced &agr;‐synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy , 2019, European journal of pharmacology.

[2]  D. Eliezer,et al.  Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde. , 2018, ACS chemical neuroscience.

[3]  A. Whitworth,et al.  Superoxide Radical Dismutation as New Therapeutic Strategy in Parkinson’s Disease , 2018, Aging and disease.

[4]  J. Fitzgerald,et al.  The Therapeutic Potential of Metformin in Neurodegenerative Diseases , 2018, Front. Endocrinol..

[5]  D. Goldstein,et al.  3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by N-Acetylcysteine , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[6]  S. Crovella,et al.  MAO‐B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease , 2018, Journal of clinical pharmacology.

[7]  K. Ye,et al.  α‐Synuclein stimulation of monoamine oxidase‐B and legumain protease mediates the pathology of Parkinson's disease , 2018, The EMBO journal.

[8]  V. Giorgio,et al.  Dopamine Oxidation Products as Mitochondrial Endotoxins, a Potential Molecular Mechanism for Preferential Neurodegeneration in Parkinson's Disease. , 2018, ACS chemical neuroscience.

[9]  D. Krainc,et al.  LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson’s disease , 2018, Proceedings of the National Academy of Sciences.

[10]  J. Andersen,et al.  An inducible MAO-B mouse model of Parkinson’s disease: a tool towards better understanding basic disease mechanisms and developing novel therapeutics , 2018, Journal of Neural Transmission.

[11]  L. Bubacco,et al.  Diabetes Mellitus as a Risk Factor for Parkinson’s Disease: a Molecular Point of View , 2018, Molecular Neurobiology.

[12]  A. De Simone,et al.  Order and disorder in the physiological membrane binding of α-synuclein. , 2018, Current opinion in structural biology.

[13]  Christopher V. Rao,et al.  Ancient Regulatory Role of Lysine Acetylation in Central Metabolism , 2017, mBio.

[14]  S. Schneider,et al.  Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature , 2017, Movement disorders : official journal of the Movement Disorder Society.

[15]  Subhojit Roy.  Synuclein and dopamine: the Bonnie and Clyde of Parkinson's disease , 2017, Nature Neuroscience.

[16]  D. Murry,et al.  Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde. , 2017, Biochemical and biophysical research communications.

[17]  D. Surmeier,et al.  Parkinson's Disease Is Not Simply a Prion Disorder , 2017, The Journal of Neuroscience.

[18]  G. Jeong,et al.  Metformin lowers α-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson's disease , 2017, Neuropharmacology.

[19]  J. Schultze,et al.  Inflammasome-driven catecholamine catabolism in macrophages blunts lipolysis in the aged , 2017, Nature.

[20]  Sohee Jeon,et al.  Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease , 2017, Science.

[21]  R. Kalb,et al.  Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration , 2017, Nature Neuroscience.

[22]  Michael L. Wallace,et al.  Multi-transmitter neurons in the mammalian central nervous system , 2017, Current Opinion in Neurobiology.

[23]  D. Lovinger,et al.  Aldehyde dehydrogenase 1–positive nigrostriatal dopaminergic fibers exhibit distinct projection pattern and dopamine release dynamics at mouse dorsal striatum , 2017, Scientific Reports.

[24]  N. Seyfried,et al.  Asparagine endopeptidase cleaves α-synuclein and mediates pathologic activities in Parkinson's disease , 2017, Nature Structural &Molecular Biology.

[25]  A. Bax,et al.  Superoxide is the critical driver of DOPAL autoxidation, lysyl adduct formation, and crosslinking of α-synuclein. , 2017, Biochemical and biophysical research communications.

[26]  O. Mabrouk,et al.  Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice , 2017, Acta neuropathologica communications.

[27]  K. Thorn,et al.  α-Synuclein Promotes Dilation of the Exocytotic Fusion Pore , 2017, Nature Neuroscience.

[28]  D. Krainc,et al.  α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies , 2017, Nature Medicine.

[29]  O. Tysnes,et al.  Epidemiology of Parkinson’s disease , 2017, Journal of Neural Transmission.

[30]  Ole Isacson,et al.  The Threshold Theory for Parkinson's Disease , 2017, Trends in Neurosciences.

[31]  D. James Surmeier,et al.  Selective neuronal vulnerability in Parkinson disease , 2017, Nature Reviews Neuroscience.

[32]  L. Bubacco,et al.  DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function , 2017, Scientific Reports.

[33]  R. Strong,et al.  Neurochemical and motor changes in mice with combined mutations linked to Parkinson’s disease , 2017, Pathobiology of aging & age related diseases.

[34]  D. Goldstein,et al.  Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies. , 2016, Parkinsonism & related disorders.

[35]  M. Khaniani,et al.  Genetic Analysis of the ZNF512B, SLC41A1, and ALDH2 Polymorphisms in Parkinson's Disease in the Iranian Population. , 2016 .

[36]  H. Cai,et al.  Role of ADH2 and ALDH2 gene polymorphisms in the development of Parkinson's disease in a Chinese population. , 2016, Genetics and molecular research : GMR.

[37]  S. Valentine,et al.  Acetylation within the First 17 Residues of Huntingtin Exon 1 Alters Aggregation and Lipid Binding. , 2016, Biophysical journal.

[38]  R. Wu,et al.  Aldehyde dehydrogenase 2 is associated with cognitive functions in patients with Parkinson’s disease , 2016, Scientific Reports.

[39]  A. Bax,et al.  Nuclear Magnetic Resonance Observation of α-Synuclein Membrane Interaction by Monitoring the Acetylation Reactivity of Its Lysine Side Chains , 2016, Biochemistry.

[40]  M. Ivanova,et al.  Neurotoxicity of the Parkinson Disease-Associated Pesticide Ziram Is Synuclein-Dependent in Zebrafish Embryos , 2016, Environmental health perspectives.

[41]  J. Doorn,et al.  Antioxidant-Mediated Modulation of Protein Reactivity for 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopamine Metabolite. , 2016, Chemical research in toxicology.

[42]  Abid Oueslati.  Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade? , 2016, Journal of Parkinson's disease.

[43]  L. Bubacco,et al.  Lysines, Achilles’ heel in alpha-synuclein conversion to a deadly neuronal endotoxin , 2016, Ageing Research Reviews.

[44]  D. Krainc,et al.  Detection of Free and Protein-Bound ortho-Quinones by Near-Infrared Fluorescence. , 2016, Analytical chemistry.

[45]  D. Goldstein,et al.  Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[46]  P. Riederer,et al.  Aldehyde dehydrogenase (ALDH) in Alzheimer’s and Parkinson’s disease , 2016, Journal of Neural Transmission.

[47]  Y. Sharabi,et al.  DOPAL is transmissible to and oligomerizes alpha-synuclein in human glial cells , 2016, Autonomic Neuroscience.

[48]  Jacqueline Burré.  The Synaptic Function of α-Synuclein , 2015, Journal of Parkinson's disease.

[49]  Jun B. Ding,et al.  Aldehyde dehydrogenase 1a1 mediates a GABA synthesis pathway in midbrain dopaminergic neurons , 2015, Science.

[50]  D. Eliezer,et al.  Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL)* , 2015, The Journal of Biological Chemistry.

[51]  Xiong Zhang,et al.  Aldehyde dehydrogenase 2 genetic variations may increase susceptibility to Parkinson's disease in Han Chinese population , 2015, Neurobiology of Aging.

[52]  L. Bubacco,et al.  Analysis of the Catecholaminergic Phenotype in Human SH-SY5Y and BE(2)-M17 Neuroblastoma Cell Lines upon Differentiation , 2015, PloS one.

[53]  D. Selkoe,et al.  KTKEGV repeat motifs are key mediators of normal α-synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity , 2015, Proceedings of the National Academy of Sciences.

[54]  A. M. Ribeiro,et al.  Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long‐Standing Model , 2015, Brain pathology.

[55]  D. Lovinger,et al.  Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression. , 2015, Human molecular genetics.

[56]  D. Mash,et al.  Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy. , 2015, Parkinsonism & related disorders.

[57]  J. Goudreau,et al.  Methylmercury impairs canonical dopamine metabolism in rat undifferentiated pheochromocytoma (PC12) cells by indirect inhibition of aldehyde dehydrogenase. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[58]  S. Kügler,et al.  Extracellular vesicle sorting of α-Synuclein is regulated by sumoylation , 2015, Acta Neuropathologica.

[59]  C. van Broeckhoven,et al.  Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. , 2015, Trends in genetics : TIG.

[60]  Matthew R. Pratt,et al.  Extent of inhibition of α-synuclein aggregation in vitro by SUMOylation is conjugation site- and SUMO isoform-selective. , 2015, Biochemistry.

[61]  P. Greengard,et al.  Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update , 2014, Front. Neuroanat..

[62]  H. Cai,et al.  Aldehyde Dehydrogenase 1 making molecular inroads into the differential vulnerability of nigrostriatal dopaminergic neuron subtypes in Parkinson’s disease , 2014, Translational Neurodegeneration.

[63]  D. Goldstein,et al.  Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. , 2014, Pharmacology & therapeutics.

[64]  A. Xu,et al.  Functional polymorphisms of the MAO gene with Parkinson disease susceptibility: A meta-analysis , 2014, Journal of the Neurological Sciences.

[65]  D. Mochly‐Rosen,et al.  Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism , 2014, Experimental Neurology.

[66]  G. Braus,et al.  Interplay between Sumoylation and Phosphorylation for Protection against α-Synuclein Inclusions* , 2014, The Journal of Biological Chemistry.

[67]  J. Casida,et al.  Benomyl, Aldehyde Dehydrogenase, DOPAL, and the Catecholaldehyde Hypothesis for the Pathogenesis of Parkinson’s Disease , 2014, Chemical research in toxicology.

[68]  H. Cai,et al.  Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation. , 2014, The Journal of clinical investigation.

[69]  C. Cavada,et al.  Is Parkinson's Disease a Vesicular Dopamine Storage Disorder? Evidence from a Study in Isolated Synaptic Vesicles of Human and Nonhuman Primate Striatum , 2014, The Journal of Neuroscience.

[70]  H. Urlaub,et al.  Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins , 2014, Science.

[71]  D. Goldstein,et al.  Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein , 2014, Neuroscience Letters.

[72]  D. D. Di Monte,et al.  Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation , 2014, Cell Death and Disease.

[73]  B. Ritz,et al.  Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease , 2014, Neurology.

[74]  Luigi Bubacco,et al.  Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease? , 2014, Ageing Research Reviews.

[75]  A. Björklund,et al.  NURR1 in Parkinson disease—from pathogenesis to therapeutic potential , 2013, Nature Reviews Neurology.

[76]  Richard Wade-Martins,et al.  Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model , 2013, Proceedings of the National Academy of Sciences.

[77]  J. R. Santos,et al.  Cognitive, motor and tyrosine hydroxylase temporal impairment in a model of parkinsonism induced by reserpine , 2013, Behavioural Brain Research.

[78]  D. Mash,et al.  Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease , 2013, Journal of neurochemistry.

[79]  S. Goldwurm,et al.  Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease , 2013, Neurobiology of Aging.

[80]  Daniel Weindl,et al.  Complexity of dopamine metabolism , 2013, Cell Communication and Signaling.

[81]  L. Bubacco,et al.  Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[82]  D. Surmeier,et al.  Neuronal vulnerability, pathogenesis, and Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[83]  B. Ritz,et al.  Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease , 2012, Proceedings of the National Academy of Sciences.

[84]  D. Goldstein,et al.  Vesicular uptake blockade generates the toxic dopamine metabolite 3,4‐dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease , 2012, Journal of neurochemistry.

[85]  J. Doorn,et al.  Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity , 2012, Brain Research.

[86]  B. Sabatini,et al.  Dopaminergic neurons inhibit striatal output via non-canonical release of GABA , 2012, Nature.

[87]  D. Lovinger,et al.  Conditional Expression of Parkinson's Disease-Related Mutant α-Synuclein in the Midbrain Dopaminergic Neurons Causes Progressive Neurodegeneration and Degradation of Transcription Factor Nuclear Receptor Related 1 , 2012, The Journal of Neuroscience.

[88]  Vindhya Koppaka,et al.  Aldehyde Dehydrogenase Inhibitors: a Comprehensive Review of the Pharmacology, Mechanism of Action, Substrate Specificity, and Clinical Application , 2012, Pharmacological Reviews.

[89]  D. Goldstein,et al.  Neurodegeneration and Motor Dysfunction in Mice Lacking Cytosolic and Mitochondrial Aldehyde Dehydrogenases: Implications for Parkinson's Disease , 2012, PloS one.

[90]  C. Perrone-Capano,et al.  Direct Regulation of Pitx3 Expression by Nurr1 in Culture and in Developing Mouse Midbrain , 2012, PloS one.

[91]  J. Schneider,et al.  Functional significance of aldehyde dehydrogenase ALDH1A1 to the nigrostriatal dopamine system , 2011, Brain Research.

[92]  Y. Sharabi,et al.  Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases. , 2011, The Journal of clinical investigation.

[93]  J. Doorn,et al.  Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite. , 2011, Neurotoxicology.

[94]  J. Doorn,et al.  Oxidation of 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopaminergic Metabolite, to a Semiquinone Radical and an ortho-Quinone* , 2011, The Journal of Biological Chemistry.

[95]  Richard Wade-Martins,et al.  Functional Alterations to the Nigrostriatal System in Mice Lacking All Three Members of the Synuclein Family , 2011, The Journal of Neuroscience.

[96]  D. Goldstein,et al.  Catechols in post‐mortem brain of patients with Parkinson disease , 2011, European journal of neurology.

[97]  Beate Ritz,et al.  Parkinson’s disease risk from ambient exposure to pesticides , 2011, European Journal of Epidemiology.

[98]  Fred H. Gage,et al.  In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.

[99]  W. Burke,et al.  The Neurotoxicity of DOPAL: Behavioral and Stereological Evidence for Its Role in Parkinson Disease Pathogenesis , 2010, PloS one.

[100]  T. Südhof,et al.  α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro , 2010, Science.

[101]  L. Bubacco,et al.  Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. , 2010, Biochimica et biophysica acta.

[102]  J. Henley,et al.  Mechanisms, regulation and consequences of protein SUMOylation. , 2010, The Biochemical journal.

[103]  D. Mochly‐Rosen,et al.  Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant , 2010, Nature Structural &Molecular Biology.

[104]  R. Nicoll,et al.  Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis , 2010, Neuron.

[105]  R. Seegal,et al.  Methylmercury inhibits dopaminergic function in rat pup synaptosomes in an age-dependent manner. , 2009, Neurotoxicology and teratology.

[106]  J. Doorn,et al.  Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. , 2009, Chemical research in toxicology.

[107]  M. Cascio,et al.  Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells , 2009, Neurobiology of Disease.

[108]  S. Strack,et al.  Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate. , 2009, Chemical research in toxicology.

[109]  D. Krainc,et al.  Acetylation Targets Mutant Huntingtin to Autophagosomes for Degradation , 2009, Cell.

[110]  Min Zhang,et al.  Molecular Cloning and Oxidative Modification of Human Lens ALDH1A1: Implication in Impaired Detoxification of Lipid Aldehydes , 2009, Journal of toxicology and environmental health. Part A.

[111]  M. Chesselet,et al.  Ziram Causes Dopaminergic Cell Damage by Inhibiting E1 Ligase of the Proteasome* , 2008, Journal of Biological Chemistry.

[112]  M. Disatnik,et al.  Activation of Aldehyde Dehydrogenase-2 Reduces Ischemic Damage to the Heart , 2008, Science.

[113]  C. Brocker,et al.  Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily , 2008, Expert opinion on drug metabolism & toxicology.

[114]  J. Andersen,et al.  MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology , 2008, PloS one.

[115]  Cornelius J Werner,et al.  Proteome analysis of human substantia nigra in Parkinson's disease , 2008, Proteome Science.

[116]  S. Cragg,et al.  Increased striatal dopamine release and hyperdopaminergic‐like behaviour in mice lacking both alpha‐synuclein and gamma‐synuclein , 2008, The European journal of neuroscience.

[117]  W. Burke,et al.  Aggregation of α-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine , 2008, Acta Neuropathologica.

[118]  B. Cagniard,et al.  Unregulated Cytosolic Dopamine Causes Neurodegeneration Associated with Oxidative Stress in Mice , 2008, The Journal of Neuroscience.

[119]  J. Doorn,et al.  Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate. , 2007, Chemical research in toxicology.

[120]  Gary W. Miller,et al.  Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration , 2007, The Journal of Neuroscience.

[121]  M. Smidt,et al.  Retinoic acid counteracts developmental defects in the substantia nigra caused by Pitx3 deficiency , 2007, Development.

[122]  V. Vasiliou,et al.  Neurotoxicity and Metabolism of the Catecholamine-Derived 3,4-Dihydroxyphenylacetaldehyde and 3,4-Dihydroxyphenylglycolaldehyde: The Role of Aldehyde Dehydrogenase , 2007, Pharmacological Reviews.

[123]  J. Mellor,et al.  SUMOylation regulates kainate-receptor-mediated synaptic transmission , 2007, Nature.

[124]  D. Sulzer,et al.  Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease , 2007, Trends in Neurosciences.

[125]  L. Moran,et al.  The medial and lateral substantia nigra in Parkinson’s disease: mRNA profiles associated with higher brain tissue vulnerability , 2007, Neurogenetics.

[126]  G. Gerhardt,et al.  Monoamine metabolism and behavioral responses to ethanol in mitochondrial aldehyde dehydrogenase knockout mice. , 2006, Alcoholism, clinical and experimental research.

[127]  P. Carvey,et al.  Progressive Dopamine Neuron Loss in Parkinson's Disease: The Multiple Hit Hypothesis , 2006, Cell transplantation.

[128]  D. Selkoe,et al.  Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.

[129]  Vellareddy Anantharam,et al.  Dieldrin-induced neurotoxicity: relevance to Parkinson's disease pathogenesis. , 2005, Neurotoxicology.

[130]  S. Mandel,et al.  Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes , 2004, Journal of Neural Transmission.

[131]  J. Costentin,et al.  Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: relationships with 3,4-dihydroxyphenylacetaldehyde formation. , 2004, Neurotoxicology.

[132]  V. Vasiliou,et al.  Role of Human Aldehyde Dehydrogenases in Endobiotic and Xenobiotic Metabolism , 2004, Drug metabolism reviews.

[133]  Dagmar Galter,et al.  ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia , 2003, Neurobiology of Disease.

[134]  D. S. Zahm,et al.  3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson’s disease pathogenesis , 2003, Brain Research.

[135]  V. Vasiliou,et al.  Molecular cloning and baculovirus expression of the rabbit corneal aldehyde dehydrogenase (ALDH1A1) cDNA. , 2003, DNA and cell biology.

[136]  Chris Zarow,et al.  Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. , 2003, Archives of neurology.

[137]  T. Fukagawa,et al.  Ubc9 is essential for viability of higher eukaryotic cells. , 2002, Experimental cell research.

[138]  Ted M. Dawson,et al.  Neuroprotective and neurorestorative strategies for Parkinson's disease , 2002, Nature Neuroscience.

[139]  E. Cochran,et al.  Age‐related decreases in Nurr1 immunoreactivity in the human substantia nigra , 2002, The Journal of comparative neurology.

[140]  W. Burke,et al.  3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis. , 2001, Brain research. Molecular brain research.

[141]  W. Burke,et al.  Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. , 2001, Free radical biology & medicine.

[142]  W. Keung,et al.  The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin. , 2000, Journal of medicinal chemistry.

[143]  V. Vasiliou,et al.  Characterization of 4-hydroxy-2-nonenal metabolism in stellate cell lines derived from normal and cirrhotic rat liver. , 2000, Biochimica et biophysica acta.

[144]  Graeme Eisenhofer,et al.  3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells , 2000, Brain Research.

[145]  G. Eisenhofer,et al.  Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4‐dihydroxyphenylacetaldehyde , 2000, Journal of neuroscience research.

[146]  R. F. Shore,et al.  Diorthosubstituted Polychlorinated Biphenyls in Caudate Nucleus in Parkinson's Disease , 1998, Experimental Neurology.

[147]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[148]  E. Hirsch,et al.  Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease? , 1996, Neurology.

[149]  A. Klyosov,et al.  Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism. , 1996, Biochemistry.

[150]  N. Hattori,et al.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[151]  R. Strong,et al.  An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[152]  Akihiko Iwai,et al.  The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.

[153]  U. Dräger,et al.  High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[154]  J. Kurth,et al.  Association of a monoamine oxidase B allele with Parkinson's disease , 1993, Annals of neurology.

[155]  R. Pietruszko,et al.  Human aldehyde dehydrogenase. Activity with aldehyde metabolites of monoamines, diamines, and polyamines. , 1991, The Journal of biological chemistry.

[156]  C. Marsden,et al.  Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.

[157]  R. Pietruszko,et al.  Human aldehyde dehydrogenase: metabolism of putrescine and histamine. , 1987, Alcoholism, clinical and experimental research.

[158]  D. Petersen,et al.  The oxidation of α-β unsaturated aldehydic products of lipid peroxidation by rat liver aldehyde dehydrogenases☆ , 1987 .

[159]  Alexander D. MacKerell,et al.  Chemical modification of human aldehyde dehydrogenase by physiological substrate. , 1987, Biochimica et biophysica acta.

[160]  Alexander D. MacKerell,et al.  Human aldehyde dehydrogenase: kinetic identification of the isozyme for which biogenic aldehydes and acetaldehyde compete. , 1986, Alcoholism, clinical and experimental research.

[161]  Y. Agid,et al.  Monoamine oxidase and aldehyde dehydrogenase activity in the striatum of rats after 6‐hydroxydopamine lesion of the nigrostriatal pathway , 1973, British journal of pharmacology.

[162]  D. Eliezer,et al.  Role of Parkinson’s Disease-linked Mutations and N-Terminal Acetylation on the Oligomerization of α -Synuclein Induced by DOPAL , 2019 .

[163]  M. Khaniani,et al.  Genetic Analysis of the ZNF512B, SLC41A1, and ALDH2 Polymorphisms in Parkinson's Disease in the Iranian Population. , 2016, Genetic testing and molecular biomarkers.

[164]  Brigitte C Vanle,et al.  Aldehyde dehydrogenase inhibition generates a reactive dopamine metabolite autotoxic to dopamine neurons. , 2014, Parkinsonism & related disorders.

[165]  T. Nickl-Jockschat,et al.  Aldehyde dehydrogenase 2 in sporadic Parkinson's disease. , 2014, Parkinsonism & related disorders.

[166]  J. Doorn,et al.  Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal. , 2007, Neurotoxicology.

[167]  S. Mandel,et al.  Gene and protein signatures in sporadic Parkinson's disease and a novel genetic model of PD. , 2007, Parkinsonism & related disorders.

[168]  H. Parvez,et al.  Monoamine oxidase expression during development and aging. , 2004, Neurotoxicology.

[169]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[170]  R. Holmes,et al.  Human corneal and lens aldehyde dehydrogenases. Purification and properties of human lens ALDH1 and differential expression as major soluble proteins in human lens (ALDH1) and cornea (ALDH3). , 1997, Advances in experimental medicine and biology.

[171]  A. Yoshida,et al.  Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. , 1992, Enzyme.

[172]  D. Petersen,et al.  The oxidation of alpha-beta unsaturated aldehydic products of lipid peroxidation by rat liver aldehyde dehydrogenases. , 1987, Toxicology and applied pharmacology.